{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:35:33Z","timestamp":1648820133586},"reference-count":4,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2015.0120a","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:24:09Z","timestamp":1525253049000},"source":"Crossref","is-referenced-by-count":0,"title":["Better Risk Assessment for Individual Substances"],"prefix":"10.3238","author":[{"given":"Roland W.","family":"Freudenmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ninja","family":"Freudenmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Zurowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Sch\u00f6nfeldt-Lecuona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard J.","family":"Connemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Gahr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Freudenmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2015,2,13]]},"reference":[{"key":"10.3238\/arztebl.2015.0120a_ref1","doi-asserted-by":"crossref","unstructured":"Diaper A, Rich AS, Wilson SJ, et al.: Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Human Psychopharmacology 2013. doi: 10.1002\/hup.2346. [Epub ahead of print]","DOI":"10.1002\/hup.2346"},{"key":"10.3238\/arztebl.2015.0120a_ref2","doi-asserted-by":"crossref","unstructured":"Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM: Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Current medical research and opinion 2007; 23: 1303\u201318.","DOI":"10.1185\/030079907X188107"},{"key":"10.3238\/arztebl.2015.0120a_ref3","doi-asserted-by":"crossref","unstructured":"Wilens TE, Hammerness PG, Biederman J, et al.: Blood pressure changes associated with medication treatment of adults with attention-deficit\/hyperactivity disorder. The Journal of clinical psychiatry 2005; 66: 253\u20139.","DOI":"10.4088\/JCP.v66n0215"},{"key":"10.3238\/arztebl.2015.0120a_ref4","doi-asserted-by":"crossref","unstructured":"Weber F, Anlauf M: Treatment resistant hypertension\u2014investigation and conservative management. Dtsch Arztebl Int 2014; 111: 425\u201331.","DOI":"10.3238\/arztebl.2014.0425"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0120a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:21:27Z","timestamp":1638796887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0120a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,13]]},"references-count":4,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2015.0120a","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,13]]}}}